Document Detail


r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study.
MedLine Citation:
PMID:  8542869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapeutic strategies for patients with unstable angina have been hampered by the difficulty in defining a homogenous cohort of patients, and identifying their risk for subsequent cardiovascular events. Despite the similarities in pathophysiological mechanisms between unstable angina and acute myocardial infarction, an analysis of recent trials of thrombolytic therapy in unstable angina has failed to reveal evidence of improved clinical outcome. However, both aspirin and heparin have shown evidence of benefit and in order to test more specific and potent thrombin inhibitors (for example hirudin) it is necessary to identify a cohort of patients with a high risk of subsequent cardiac events. This small scale pilot study set out to identify patients with unstable angina or non-Q wave infarction with a high risk of subsequent cardiac events, and to undertake a feasibility study of two dose regimens of recombinant hirudin (HPW023). The impact on haemostatic parameters and the need for dose adjustment in order to achieve the target therapeutic range of activated partial thromboplastin time (aPTT) was also assessed. Firstly, the study revealed that it was possible to identify a high risk patient population (6/43, 14% had sustained infarction; 10/43, 23% required emergency or urgent revascularization and 11/43, 26% elective revascularization). Secondly, it was possible to achieve stable antithrombin regimens with the two selected doses of hirudin (at least 78% of patients were within the target range at any of the time points). Haemostatic parameters were compared, but larger scale studies are required to establish safety, with a reliable estimate of the impact of hirudin on clinical events.
Authors:
K A Fox
Related Documents :
19945179 - Diastolic function in children with kawasaki disease.
2913729 - Comparison of mortality and myocardial infarction rates in stable angina pectoris with ...
16008159 - Follow-up of patients undergoing percutaneous coronary intervention.
4036819 - Frequency of intracoronary filling defects by angiography in angina pectoris at rest.
1594169 - The effect of atenolol on dipyridamole 201tl myocardial perfusion tomography in patient...
16256869 - A new anatomic score for prognosis after cardiac catheterization in patients with previ...
18574609 - Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent sui...
11526519 - Dental metal allergy in patients with oral, cutaneous, and genital lichenoid reactions.
7285319 - [14c]oxalate absorption by normal persons, calcium oxalate stone formers, and patients ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  16 Suppl D     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1995 Jul 
Date Detail:
Created Date:  1996-02-14     Completed Date:  1996-02-14     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  28-32     Citation Subset:  IM    
Affiliation:
Cardiovascular Research Unit, University of Edinburgh.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angina, Unstable / drug therapy*
Antithrombins / therapeutic use*
Hirudin Therapy*
Humans
Pilot Projects
Recombinant Proteins / therapeutic use
Chemical
Reg. No./Substance:
0/Antithrombins; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pi...
Next Document:  Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy...